Given the resistance of EGFR-altered tumors to conventional EGFR inhibitors, ongoing research into combination therapies and novel targeted approaches remains critical for improving treatment efficacy in EGFR-mutant GBM. This evidence concerns the gene EGFR and glioblastoma.